As described by the latest WHO classification of AML [8], mutations in NPM1 (without concomitant FLT3-ITD) and biallelic mutations of CEBPA in cytogenetically normal patients are associated with a favorable prognosis, whereas RUNX1 mutations have been implicated in worse overall survival in AML patients. Here, NPM1 is linked to acute myeloid leukemia.